Meeting
2013 ASCO Annual Meeting
Phase I study of TH-302, an investigational hypoxia-targeted drug, and dexamethasone in patients with relapsed/refractory multiple myeloma.
Authors
Irene M. Ghobrial
Dana-Farber Cancer Institute, Boston, MA
Irene M. Ghobrial , Jacob Laubach , Philippe Armand , Erica Boswell , Courtney Hanlon , Stacey Chuma , Esther Dawn Chu , Damian Handisides , Stew Kroll , Barbara Hickingbottom , Kenneth Carl Anderson , Paul Gerard Guy Richardson
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lymphoma and Plasma Cell Disorders
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Multiple Myeloma
Clinical Trial Registration Number
NCT01522872
Citation
J Clin Oncol 31, 2013 (suppl; abstr 8602)
DOI
10.1200/jco.2013.31.15_suppl.8602
Abstract #
8602
Poster Bd #
55G
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
MM-005: A phase I trial of pomalidomide, bortezomib, and low-dose dexamethasone (PVD) in relapsed and/or refractory multiple myeloma (RRMM).
First Author: Paul Gerard Guy Richardson
Poster
2012 ASCO Annual Meeting
Weekly dosing of the investigational oral proteasome inhibitor MLN9708 in patients (pts) with relapsed/refractory multiple myeloma (MM): A phase I study.
First Author: Shaji Kumar
Poster
2023 ASCO Annual Meeting
Phase 1 study of tasquinimod, an S100A9 inhibitor, alone and in combination with IRd for relapsed and refractory multiple myeloma (RRMM).
First Author: Dan T. Vogl
Poster
2015 ASCO Annual Meeting
Updated results from CHAMPION-1, a phase I/II study investigating weekly carfilzomib with dexamethasone for patients (Pts) with relapsed or refractory multiple myeloma (RRMM).
First Author: James R. Berenson